References
- JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
- WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol201693427071706
- WuJSavoojiJLiuDSecond- and third-generation ALK inhibitors for non-small cell lung cancerJ Hematol Oncol201691926951079
- MaWGilliganBMYuanJLiTCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyJ Hematol Oncol2016914727234522
- XiaoHQTianRHZhangZHDuKQNiYMEfficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysisOncoTargets Ther2016914711476
- GenovaCRijavecETruiniAPemetrexed for the treatment of non-small cell lung cancerExpert Opin Pharmacother201314111545155823683110
- EttingerDSAkerleyWBorghaeiHNon-small cell lung cancerJ National Compr Cancer Netw2012101012361271
- HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
- FossellaFVDeVoreRKerrRNRandomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study groupJ Clin Oncol200018122354236210856094
- AsahinaHSekineIHorinouchiHRetrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancerClin Lung Cancer2012131394321890422
- SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- SpratlinJLCohenRBEadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol201028578078720048182
- GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
- MiYJLiangYJHuangHBApatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersCancer Res201070207981799120876799
- HuXZhangJXuBMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInt J Cancer201413581961196924604288
- LiJQinSXuJRandomized, double-blind, placebo-controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
- LinCWangSXieWZhengRGanYChangJApatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwayOncotarget Epub201681
- RamalingamSSDahlbergSELangerCJOutcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599J Clin Oncol2008261606518165641